

AUG. 24. 2005 2:13PM

AVENTIS US PAT DEPT

RECEIVED
CENTRAL FAX CENTER

NO. 7743 P. 3

AUG 24 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
Klebl et al.

Examiner: **J. HAMA**

Application No.: **10/736,801**

Art Unit: **1632**

Filed: **December 16, 2003**

Title: **METHOD FOR GENERATING A
GENETICALLY MODIFIED ORGANISM**

TELEFAX CERTIFICATE

I hereby certify that this correspondence is being
transmitted via facsimile 571-273-8300 to the
Commissioner for Patents, Alexandria, VA 22313, on

8-24-05
Date of Transmission

Manuela Barret
Signature

RESPONSE TO OFFICE COMMUNICATION

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In response to the Office Action mailed June 16, 2005 requiring further restriction
of the claim 8 to an elected species, Applicants elect eukaryotic cell.

The Commissioner is authorized to charge any additional fees or credit any
overpayment necessitated by this response to Deposit Account No. 18-1982.

Respectfully submitted,

Karen I. Krupen
Karen I. Krupen, Reg. No. 34,647
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-4658
Telefax (908) 231-2626